A5037268627- Cardiac Arrhythmias and Treatments
- Atrial Fibrillation Management and Outcomes
- Cardiac pacing and defibrillation studies
- Cardiac electrophysiology and arrhythmias
- Obstructive Sleep Apnea Research
- Cardiac Imaging and Diagnostics
- Cardiomyopathy and Myosin Studies
- Cardiovascular Effects of Exercise
- COVID-19 and healthcare impacts
- Advanced MRI Techniques and Applications
- Venous Thromboembolism Diagnosis and Management
- Neuroscience of respiration and sleep
- Telemedicine and Telehealth Implementation
- Sarcoidosis and Beryllium Toxicity Research
- Cardiac Structural Anomalies and Repair
- ECG Monitoring and Analysis
- Central Venous Catheters and Hemodialysis
- Cardiovascular Syncope and Autonomic Disorders
- Cardiac, Anesthesia and Surgical Outcomes
- Healthcare Systems and Public Health
- COVID-19 Clinical Research Studies
- Patient Satisfaction in Healthcare
- Health Systems, Economic Evaluations, Quality of Life
- Cardiac Valve Diseases and Treatments
- Cardiac tumors and thrombi
Saint Luke's Hospital
2016-2025
University of Missouri–Kansas City
2013-2024
American Heart Institute
2023-2024
Saint Luke's Health System
2020-2024
St Luke's Hospital
2020
Medtronic (United States)
2020
University of Kansas
2020
Heart Institute
2015
University of Michigan
2007-2014
Detroit Medical Center
2014
The ADVENT randomized trial revealed no significant difference in 1-year freedom from atrial arrhythmias (AA) between thermal (radiofrequency/cryoballoon) and pulsed field ablation (PFA). However, recent studies indicate that the postablation AA burden is a better predictor of clinical outcomes than dichotomous endpoint 30-second recurrence. goal this study was to determine: 1) impact on outcomes; 2) effect modality burden. In ADVENT, symptomatic drug-refractory patients with paroxysmal...
The purpose of this study was to assess whether delayed enhancement (DE) on MRI is associated with ventricular tachycardia (VT)/ventricular fibrillation or death in patients cardiac sarcoidosis and left ejection fraction >35%. Fifty-one >35% underwent DE-MRI. DE assessed by visual scoring quantified the full-width at half-maximum method. were followed for 48.0 ± 20.2 months. Twenty-two 51 (63%) had DE. Forty no prior history VT (primary prevention cohort). Among those, 3 developed 2 died....
BackgroundPulmonary vein isolation (PVI) is the cornerstone of catheter ablation to treat patients with symptomatic drug-refractory atrial fibrillation (AF).ObjectiveThe purpose this study was assess safety and efficacy PVI using cryoballoon persistent AF.MethodsSTOP Persistent AF (ClinicalTrials.gov Identifier: NCT03012841) a prospective, multicenter, single-arm, Food Drug Administration–regulated trial designed evaluate PVI-only for (continuous episodes <6 months). The primary endpoint...
Background— The prevalence of epicardial idiopathic ventricular arrhythmias that can be ablated from within the coronary venous system (CVS) has not been described. Methods and Results— In a consecutive group 189 patients with referred for ablation, site origin (SOO) tachycardia and/or premature contractions was determined by activation mapping pace mapping. Mapping performed CVS if endocardial did reveal an SOO. Venography angiography were before ablation in CVS. 27 (14%±5%; 95% confidence...
Complications of Atrial Fibrillation Ablation. Introduction: Up to 6% patients experience complications after radiofrequency catheter ablation (RFA) atrial fibrillation (AF). The purpose this study is determine the prevalence and predictors periprocedural RFA for AF. Methods Results: subjects were 1,295 consecutive (age = 60 ± 10 years) who underwent (n 1,642) paroxysmal (53%) or persistent AF (47%) from January 2007 2010. A complication occurred in 57 (3.5%); a vascular access 31 (1.9%);...
Background— Because of the increased use pacemakers and implantable cardioverter defibrillators, infection has become a complication with significant morbidity mortality. Data on risk factors for mortality in patients cardiac-device related are limited. We evaluated prognostic significance key clinical echocardiographic variables large retrospective population infection. Methods Results— Two hundred ten were identified at University Michigan between 1995 2006. abstracted variables, treatment...
Atrial fibrillation (AF) is the most common clinically significant arrhythmia, and it increases stroke risk. A preventive approach to AF needed because virtually all treatments such as cardioversion, antiarrhythmic drugs, ablation, anticoagulation are associated with high cost carry systematic review was performed identify effective lifestyle-based strategies for reducing primary secondary AF. PubMed search using articles up March 1, 2021. Search terms included atrial fibrillation, flutter,...
The remedē System Pivotal Trial was a prospective, multi-center, randomized trial demonstrating transvenous phrenic nerve stimulation (TPNS) therapy is safe and effectively treats central sleep apnea (CSA) improves architecture daytime sleepiness. Subsequently, the approved by FDA in 2017. As condition of approval, Post Approval Study (PAS) collected clinical evidence regarding long-term safety effectiveness adults with moderate to severe CSA through five years post implant.Patients...
ABSTRACT Background While manual compression (MC) remains the standard of care to achieve hemostasis, a novel vascular closure device (VCD) was designed faster hemostasis without compromising safety. The objective ReliaSeal trial evaluate safety and effectiveness Mynx Control Venous VCD close single or multiple femoral venous access sites in one both limbs patients undergoing catheter‐based procedures. Methods prospective, randomized controlled comparing MC procedures requiring utilizing up...
It is unclear whether early restoration of sinus rhythm in patients with persistent atrial arrhythmias after catheter ablation fibrillation (AF) facilitates reverse remodeling and promotes long-term maintenance rhythm. The purpose this study was to determine the relationship between time a recurrence an arrhythmia radiofrequency AF.Radiofrequency performed 384 consecutive (age 60 +/- 9 years) for paroxysmal (215 patients) or AF (169 patients). Transthoracic cardioversion all 93 (24%) who...
To explore the safety and clinical utility of MRI in participants with non-MRI-conditional cardiac implantable electronic devices, by establishing Patient Registry Magnetic Resonance Imaging Non-Approved DEvices (PROMeNADe).From September 2015 to June 2019, 532 (211 women) a mean age 69 years ± 14 (standard deviation) were enrolled prospectively PROMeNADe registry (ClinicalTrials.gov identifier: NCT03081364) underwent total 608 examinations (61 examinations). All had device interrogations...
Abstract Background Central sleep apnea (CSA) is a breathing disorder caused by the intermittent absence of central respiratory drive. Transvenous phrenic nerve stimulation new therapeutic option, recently approved FDA , for treatment CSA. Objective To describe technique used to implant transvenous system (the remedē System, Respicardia, Inc). Methods The System placed in pectoral region, typically on right side. A single lead either left pericardiophrenic vein (PPV) or brachiocephalic...
Following catheter ablation, vascular access management involves potential complications and prolonged recovery. Recently, suture-mediated closure (SMC) devices were approved for venous procedures. The objective of this study is to evaluate the safety a commercially available SMC multiple site by duplex ultrasound (DUS) in asymptomatic subjects with non-visible complications.